Skip to main content

Day: September 6, 2024

Bedford Metals Provides Corporate Update on Uranium Exploration Progress

VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) — Bedford Metals Corp. (TSX-V: BFM, FWB: O8D, ISIN: CA0762301012) (the “Company” or “Bedford”) wishes to provide a corporate update. Bedford continues to focus on advancing its uranium exploration projects in the Athabasca region of northern Saskatchewan, Canada and has made meaningful progress with its exploration initiatives. As reported in previous news releases, the Company has been actively advancing its exploration projects, particularly the Ubiquity Lake Uranium Project. Bedford is pleased with the initial results from its most recent exploration program, where the field team identified several promising targets. The Company is awaiting assay results from the samples collected during this program, which will provide further insight into the project’s potential. In...

Continue reading

TGS Awarded 2D Seismic Contract Offshore Sumatra, Indonesia

Perth, Australia (06 September 2024) – TGS, a leading global provider of energy data and intelligence, has commenced the acquisition of a 2D seismic survey in the Sumatra basin, Indonesia. The survey, conducted using COSL’s HYSY 718 vessel, is expected to comprise between 5,500- and 6,500-line kilometers, covering two regions. This initiative marks a continuation of TGS’s commitment to supporting exploration efforts in Indonesia. Earlier this year, TGS announced the completion of a multi-client 2D reprocessing project in the same basin which aims to integrate key discoveries with available open acreage, complementing TGS’s existing extensive 2D and 3D seismic datasets in the region. Kristian Johansen, CEO at TGS, stated, “North Sumatra has been the site of major discoveries in the past few years. With this being our sixth consecutive acquisition...

Continue reading

Construction contract in Estonia (office building in Tallinn)

On 5 September 2024, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, and Estconde Invest OÜ entered into a design-and-build contract of an office building located at Tartu mnt 1, Tallinn. The contract includes construction of a 27-storey class A office building with two underground floors, necessary infrastructure and surrounding territory. The building will be completed according to the international BREEAM standard at the level Excellent. The contract value is approximately EUR 64.3 million, plus value added tax. The duration of the works is 40 months. AS Merko Ehitus Eesti (merko.ee) is a recognised Estonian construction company, which offers construction services in general construction, civil engineering and residential construction. Additional information: AS Merko Ehitus Eesti, Director of the General Construction Division,...

Continue reading

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued recognition of Cresemba in meeting the critical medical needs of patients with life-threatening invasive mold infections, and its strong sales performance in Europe, which has resulted in this milestone payment. We already announced several sales milestone payments from sales in Asia...

Continue reading

Bunker Hill Announces Election To Issue Shares in Satisfaction of Financing Cooperation Fee

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR; OTCQB: BHLL) announces that it has elected to issue 506,775 shares of common stock (the “Shares”) at a deemed issue price of C$0.16 per Share to a certain creditor of the Company (the “Creditor”) in full satisfaction of the aggregate US$60,000 financing cooperation fee owing to the Creditor for the three (3) month period beginning on April 1, 2024 and ending on June 30, 2024 (the “Q2 Cooperation Fee”) pursuant to the terms of an agreement re financing cooperation dated September 27, 2022 (the “Cooperation Agreement”) entered into by and among the Company and the Creditor. The Cooperation Agreement provides for, among other things, the Creditor and its affiliates providing certain collateral security...

Continue reading

Varonis Systems, Inc. Announces Pricing of its Upsized $400 Million of Convertible Senior Notes

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS) (“Company” or “Varonis”), announced today that it priced a private offering of $400 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes will only be sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $350 million aggregate principal amount of notes. The Company also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $60 million aggregate principal amount of Notes. The sale is expected to close on September 10, 2024, subject to satisfaction of the conditions to closing. The...

Continue reading

Evergreen Corporation and Forekast Limited Announce Definitive Business Combination Agreement

Forekast connects today’s business needs to tomorrow’s technology. Forekast continues to innovate, offering flexible and scalable solutions tailored to meet the evolving needs of clients across multiple industries. NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) — Evergreen Corporation (NASDAQ: EVGR), a special purpose acquisition company (“EVGR”), today announced that they have entered into a definitive agreement and plan of merger (the “Business Combination Agreement”) under which EVGR will merge with Forekast Limited (“Forekast”). Following the closing, the combined company will operate as Forekast Group (“PubCo”). Forekast is a technology managed services provider specializing in augmented intelligence, integrating AI-driven insights to enhance business operations, customer experiences, and workforce capabilities. Forekast has a...

Continue reading

Alaska Energy Metals Closes $5 Million Special Warrant and Unit Offering; Nikolai Nickel Project Exploration Well Underway With More Than $8.68 Million Recently Raised

Highlights:An additional $5,000,000 has been raised in a second round of Special Warrant and Unit offerings, following on from first round offerings totaling $3,679,564 closed in July. More than $8.68 million has been raised between the two recent offerings. Alaska Energy Metals is now adequately funded for the drilling program planned and underway at the Nikolai nickel project in Alaska; drilling commenced in July and has been completed on the Canwell prospects. Drilling is underway to test for extensions of the Eureka nickel deposit. Metallurgical studies to determine metal recovery rates have been initiated.VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to announce that it has closed its non-brokered offering...

Continue reading

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Presbyopia, the gradual loss of ability to focus on near objects, typically becomes noticeable in the early to mid-40s. This progressive and ubiquitous...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.